Mixed Topline Data Reported in Phase 3 RAISE Trial of Ganaxolone for Refractory Status Epilepticus

Published Date: 20 Jun 2024

Marinus Pharmaceuticals reported that it will continue to analyze the full dataset and engage with the FDA to discuss the future of ganaxolone for treating refractory status epilepticus.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

How access to specialized cancer centers affects glioblastoma outcomes

2.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

3.

Positive Trials; Malignancies Increasing in Younger Adults; Andre Braugher's Cancer Dx.

4.

U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain

5.

Beyond What Is Visible in Myelofibrosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot